0001493152-26-009127
SEC filingGT Biopharma, Inc. filed a 10-Q/A for Q2 2025, which includes a restatement of interim financial data for the quarterly periods ended June 30, 2025, and September 30, 2025. The restatement was required due to an error in the classification and accounting of Greenshoe Rights related to Series L 10% Convertible Preferred Stock. Management determined that the Company did not maintain effective controls over the preparation and review of accounting for complex financial transactions, specifically with respect to the proper application of ASC 480. This control deficiency constituted a material weakness in internal control over financial reporting as of June 30, 2025, and September 30, 2025. The Company has concluded that its disclosure controls and procedures were not effective as of June 30, 2025. Subsequent to June 30, 2025, the Company adopted additional internal controls, including engaging an accounting consultant for complex transactions. No changes in internal controls over financial reporting were made during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.
No specific financial performance figures (e.g., revenue, net income) are provided in the document content for Q2 2025. The filing is a 10-Q/A that focuses on the restatement of interim financial data for the quarterly periods ended June 30, 2025, and September 30, 2025, due to an accounting error related to Greenshoe Rights. Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, and identified a material weakness in internal control over financial reporting. The Company qualifies as a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk under Item 3.
No revenue data, segment breakdown, geographic mix, or growth drivers are disclosed in the provided document content. The filing does not include financial statements or related notes in the excerpt, so revenue analysis cannot be performed based on the available information.
No margin data (e.g., gross margin, operating margin) or profitability figures are provided in the document content. The filing lacks financial statement details, preventing analysis of cost structure changes or margin trends.
No cash flow data (e.g., operating cash flow, free cash flow), balance sheet figures (e.g., debt levels, liquidity position), or related financial metrics are disclosed in the provided document content. The excerpt does not include condensed statements of cash flows or balance sheets, so this analysis cannot be conducted.
No management guidance, strategic priorities, or specific risk factors beyond the material weakness in internal control over financial reporting are disclosed in the provided document content. The Company adopted additional internal controls post-June 30, 2025, including engaging an accounting consultant for complex transactions, but no forward-looking financial projections or operational plans are mentioned. The filing indicates that no changes in internal controls over financial reporting were made during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.